Zealand Pharma — November 2022
-
Spændende at fase II studiet med BI 456906 i NASH var sat til at rekruttere 240 patienter, men endte med at rekruttere 1153 patienter: https://clinicaltrials.gov/ct2/history/NCT04771273?A=41&B=43&C=merged#StudyPageTop
-
Ligesom fedme, så er NASH et gigantisk
marked med et kæmpe unmet medical need -
@lassevedel96 - JA, lagde godt mærke til det!
-
Godmorgen
-
Q&A med Adam Steensberg d. 22. november kl. 15. Tilmelding: https://www.proinvestor.com/index.php?p=q-and-a&groupid=157
-
tak og god morgen
-
CSørensen - Jeg forventer at vi høre noget om at EASE 2 studiet status. Jeg forventer at høre noget om BI 456906 og hvad Boehringer Ingelheim vil videre. Vil også se efter Protagonist Therapeutics milepælsbetaling. Jeg froventer dette bliver positivt.
-
Jeg har ikke noget godt overblik over hvad Boehringer Ingelheim skal betale for at gå ind i fase 3 og det bliver interessant at høre om hvad tidshorisonten er på dette projekt.
-
@exitnu - point for den helgardering
-
kom så ZP
-
Zealand Pharma Announces Financial Results for the First Nine Months of 2022
Financial results for the first nine months of 2022
• Revenue: DKK 80.1 million (DKK 95.1 million in the first nine months of 2021).
• Net operating expenses: DKK -675.7 million (DKK -652.8 million in the first nine months of 2021).
• Net operating result: DKK -596.2 million (DKK -568.7 million in the first nine months of 2021).
• Net financial items: DKK -53.4 million (DKK 21.5 million in the first nine months of 202
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind